Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Mitazalimab (Synonyms: JNJ7107, JNJ-64457107, JNJ64457107, JNJ 7107, ADC-1013, AD-1013)

Catalog No. T77090 Copy Product Info
🥰Excellent
Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.

Mitazalimab

Copy Product Info
🥰Excellent
Catalog No. T77090
Synonyms JNJ7107, JNJ-64457107, JNJ64457107, JNJ 7107, ADC-1013, AD-1013

Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.

Mitazalimab
Cas No. 2055640-86-1
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$247In StockIn Stock
5 mg$645In StockIn Stock
10 mg$987-In Stock
25 mg$1,530-In Stock
50 mg$1,980-In Stock
100 mg$2,790-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95.1% (SDS-PAGE); 98.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.
In vitro
Mitazalimab (1 ng/mL-10 μg/mL) was able to activate tumor-associated macrophages (TAM) in human prostate or ovarian cancer samples. [2]
In vivo
Mitazalimab (100 μg/mouse, intraperitoneal injection, single dose) was able to activate splenic dendritic cells and B-cells in naïve hCD40tg mice and induced OVA-specific CD8+ T-cell expansion under OVA reprocessing conditions (200 μg intravenously, 3 times over 7 consecutive days). In addition, Mitazalimab (100 and 300 μg/mouse, intraperitoneal injection, administered on days 7, 10, and 13 post-inoculation) induced the release of pro-inflammatory cytokines and chemokines in the blood of animals bearing bladder tumors in MB49 mice and affected the composition of tumor bone marrow cells, resulting in a decrease in monocytes and macrophages and an increase in the number of granulocytes. [1]
SynonymsJNJ7107, JNJ-64457107, JNJ64457107, JNJ 7107, ADC-1013, AD-1013
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetTNFRSF5/CD40
Chemical Properties
Molecular Weight143.42 kDa
Cas No.2055640-86-1
Antibody Information
IsotypeHuman IgG1 lambda2
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Mitazalimab | purchase Mitazalimab | Mitazalimab cost | order Mitazalimab | Mitazalimab in vivo | Mitazalimab in vitro | Mitazalimab molecular weight